

VT

PATENTES

BIOTECNOLOGÍA SANITARIA

Degeneración macular
Diabetes
Sistema nervioso
Sistema inmune

8



asebio

**Vigilancia
Tecnológica**
2º trimestre 2015

Este Boletín de Vigilancia Tecnológica en Biotecnología aplicada al sector sanitario surge del trabajo conjunto entre la Oficina Española de Patentes y Marcas (OEPM) y ASEBIO como miembro de la Plataforma Tecnológica Española de Mercados Biotecnológicos, y se encuadra dentro de una de las actividades de colaboración que la OEPM viene llevando a cabo con las referidas Plataformas para hacer llegar a las empresas, investigadores, y organizaciones que las integran una selección de las patentes más recientemente publicadas en determinados sectores tecnológicos.

Estos Boletines trimestrales, como el resto de los elaborados por la OEPM, ofrecen una información puntual, esquemática y de rápida

lectura sobre una selección de las últimas patentes biotecnológicas publicadas en el mundo relativas a cuatro líneas de investigación concretas: Sistema Nervioso, Sistema Inmune, Diabetes y Degeneración Macular.


También incluyen noticias sobre actividades realizadas por la OEPM que puedan resultar de interés a los usuarios. Si se desea recibir este Boletín periódicamente basta con cumplimentar el correspondiente formulario de suscripción.

Se puede acceder al listado de solicitudes de patentes analizadas pulsando sobre las imágenes que aparecen a continuación.


Contenido




DEGENERACIÓN
MACULAR



DIABETES



SISTEMA NERVIOSO



SISTEMA INMUNE

Degeneración Macular

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2015038891	PENN STATE RES FOUND [US]	Functional peptide analogs of pdgf
WO2015035305	SOMALOGIC INC [US]	Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders
WO2015069668	ALLERGAN INC [US]	Method of treating conditions of the eye with an anti-vegf darpin
WO2015071348	FORMYCON AG [DE]	Pharmaceutical composition of an anti-vegf antibody
WO2015054670	GENENTECH INC [US] ; HOFFMANN LA ROCHE [CH]	Nsp4 inhibitors and methods of use

Diabetes

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2015076621	KAEL GEMVAX CO LTD [KR] ; KIM SANG JAE [KR]	Peptide having angiogenesis inhibitory activity and composition containing same
WO2015076356	KANEKA CORP [JP]	Short-chain rna detection method
WO2015074103	OMNIBLEND INNOVATION PTY LTD [AU]	Regimen and method for treatment of type 2 diabetes
WO2015069256	GEN HOSPITAL CORP [US]	Eluting matrix and uses thereof
WO2015068809	SUNTORY HOLDINGS LTD [JP]	Intestinal barrier function enhancer containing lactic acid bacteria
WO2015063616	UTI LIMITED PARTNERSHIP [CA]	Methods and compositions for sustained immunotherapy
WO2015061779	UNIV WAYNE STATE [US]; FORD HENRY HEALTH SYSTEM [US]	Methods, systems and compositions relating to cell conversion via protein induced in-vivo cell reprogramming
WO2015057177	NAT SCIENCE AND TECHNOLOGY DEV AGENCY [TH]	Aptamers bound human serum albumin and glycated human serum albumin
WO2015058139	SYMBIOCELLTECH LLC [US]	Stem cell / islet cell hybrids, generation thereof, and methods for the treatment and cure of insulin-dependent diabetes mellitus

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2015056619	NIPPON SUISAN KAISHA LTD [JP]; UNIV KYOTO [JP]	Peptide or acid addition salt thereof, food and beverage, and composition for preventing diabetes and the like
WO2015049593	DOSCH HANS-MICHAEL [CA]	Method for reversing recent-onset type 1 diabetes (t1d) by administering substance p (sp)
WO2015048868	SANOFI AVENTIS FARMAC UTICA LTDA [BR]	Composition for the treatment of diabetic ulcers, method for preparing the same and use thereof
WO2015048774	BIOACTIVE REGENERATIVE THERAPEUTICS INC [US]; UNIV MINNESOTA [US]	Biomimetic hybrid gel compositions and methods of use
WO2015042521	UNIV VIRGINIA PATENT FOUND [US]; SHARMA RAHUL [US]; OKUSA MARK D [US]	Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
WO2015042288	L2 DIAGNOSTICS LLC [US]	Assays and reagents for diagnosing type 1 diabetes
WO2015035063	SANFORD BURNHAM MED RES INST [US]	Modulation of [gamma] [delta]T cells
WO2015033831	UNIV OSAKA [JP]	Dpp-4-targeting vaccine for treating diabetes
WO2015074057	UNIV PITTSBURGH [US]	Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies
WO2015075747	COUNCIL SCIENT IND RES [IN]	Cell-penetrating peptide for biomolecule delivery
WO2015073727	AEQUUS BIOPHARMA INC [US]	Engineered glycoproteins and uses thereof
WO2015078899	ROCHE DIAGNOSTICS GMBH [DE]; HOFFMANN LA ROCHE [CH]; ROCHE DIAGNOSTICS OPERATIONS [US]	Composition comprising up-converting phosphors for detecting an analyte

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2015067947	OPTIBIOTIX LTD [GB]	Composition comprising lactobacillus plantarum
WO2015048346	PRONUTRIA INC [US]	Compositions and formulations for prevention and treatment of diabetes and obesity, and methods of production and use thereof in glucose and caloric control
WO2015071368	CHAN YOU-PING [FR]	Long-acting insulin glargine analogue
WO2015071356	NOVO NORDISK AS [DK]	Hpyy(1 -36) having a beta-homoarginine substitution at position 35
WO2015071355	NOVO NORDISK AS [DK]	Selective ppy compounds and uses thereof
WO2015071229	KEYBIOSCIENCE AG [CH]	Calcitonin mimetics for treating diseases and disorders
WO2015061493	MEDTRONIC MINIMED INC [US]	Methods and systems for inhibiting foreign-body responses in diabetic patients
WO2015067716	ZEALAND PHARMA AS [DK] ; JUST RASMUS [DK]; RIBER DITTE [DK]; SHELTON ANNE PERNILLE TOFTENG [DK]; ÖSTERLUND TORBEN [SE]; HANSEN KATE [DK]; JESSEN LENE [DK]	Glucagon-glp-1-gip triple agonist compounds
WO2015067715	ZEALAND PHARMA AS [DK]	Gip-glp-1 dual agonist compounds and methods
WO2015067636	DELENEX THERAPEUTICS AG [CH]	Binding members to il-1 beta
WO2015063306	MANCINI ALDO [IT]	Manganese superoxide dismutase variants and uses thereof
WO2015051052	MERCK SHARP & DOHME [US] ; LIN SONGNIAN [US]; YAN LIN [US]; KEKEC AHMET [US] ; ZHU YUPING [US]; HUNTER DAVID N [US]; HUO PEI [US]; FENG DANQING [US]; NARGUND RAVI P [US]; MOYES CHRISTOPHER R [US]; ZHAO ZHIQIANG [US]; PIPIK BRENDA [US]; PISSARNITSKI DMITRI [US]; DUFFY JOSEPH L [US]; GUIDRY ERIN N [US]	Glucose-responsive insulin conjugates
WO2015057908	NOVARTIS AG [CH]; BOSE AVIRUP [US] DUTTAROY ALOKESH [US]	Methods of treating diabetes and related disorders

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2015054670	GENENTECH INC [US] ; HOFFMANN LA ROCHE [CH]	Nsp4 inhibitors and methods of use
WO2015044922	WOCKHARDT LTD [IN]	Pharmaceutical composition
WO2015059302	SANOFI SA [FR]	Stable formulation of insulin glulisine
WO2015055802	ZEALAND PHARMA AS [DK] ; BOEHRINGER INGELHEIM INT [DE]	Glucagon analogues
WO2015052088	NOVO NORDISK AS [DK]	Novel derivative of an insulin analogue
WO2015062803	KAPURNIOTU APHRODITE [DE]	Modified segments of islet amyloid polypeptide
WO2015044379	INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE [FR]; UNIVERSITÉ PARIS DESCARTES [FR]; ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS APHP [FR]; CENTRE NAT RECH SCIENT [FR]	A dyrk1a polypeptide for use in preventing or treating metabolic disorders
WO2015044352	FIBROSTATIN S L [ES]	Goodpasture antigen binding protein detection and inhibition and its use in diabetes
WO2015044339	GOMEZ MARIA F [SE] ; AAKESSON LINA [SE]; LERNMARK AAKE [SE]	A new rat model for diabetic vascular complications
WO2015044292	UNIV BARCELONA AUTONOMA [ES]	Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
WO2015040190	SALURATE LTD [GB]	Diagnosis of foetal distress
WO2015035162	HARVARD COLLEGE [US]	Cas9 variants and uses thereof
WO2015040182	ZEALAND PHARMA AS [DK]	Amylin analogues
WO2015040176	BETA CELL NV [BE]	Method for the treatment of diabetes mellitus
EP2873737	INST OF BIOLOGY OF THE UNIVERSITY OF LATVIA [LV]; UNIV LATVIA [LV]	A method and a kit suitable for determining that a human subject has or is at risk of developing type 1 diabetes mellitus
EP2842965	GUBRA APS [DK]	Neuromedin U analogs comprising serum albumin binding amino acid residue
WO2012010966	EPSHTEIN OLEG ILIICH [RU]	A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders

Sistema Nervioso

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2015074165	CHEN GANG [CN]	Schizophrenogenic gene and use thereof
WO2015077578	UNIV PENNSYLVANIA [US] ; DANIELL HENRY	Compositions and methods for delivery of bioencapsulated proteins across blood-brain and retinal barriers
WO2015076282	UNIV HOKKAIDO NAT UNIV CORP [JP]	Immunosuppressant
WO2015072438	UNIV NAGOYA NAT UNIV CORP [JP]	Complementary pcr primer set for als-related gene sequence analysis, method for analyzing als-related gene sequence, and method for testing als
WO2015070009	UNIV TEXAS [US]	Vh4 antibodies against gray matter neuron and astrocyte
WO2015070212	SANGAMO BIOSCIENCES INC [US]	Methods and compositions for treating huntington's disease
WO2015063616	UTI LIMITED PARTNERSHIP [CA]	Methods and compositions for sustained immunotherapy
WO2015061856	UNIV WESTERN AUSTRALIA [AU]	Neuroprotective peptides
WO2015061826	UNIV MONASH [AU]; PEPTIDES INTERNATIONAL INC [US]; BAYLOR COLLEGE MEDICINE [US]	Novel scorpion toxin analogue and method for treating autoimmune diseases
WO2015060650	VIROMED CO LTD [KR]	Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2015061367	TEVA PHARMA [IL]; TEVA PHARMA [US] TCHELET AMIR [IL]; HAYDEN MICHAEL [IL]; HAYARDENY LIAT [IL]; ROSS COLIN JAMES DOUGLAS [CA]; GROSSMAN IRIS [IL]; LADKANI DAVID [IL]	Genetic markers predictive of response to glatiramer acetate
WO2015061330	VACCINEX INC [US]	Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
WO2015057177	NAT SCIENCE AND TECHNOLOGY DEV AGENCY [TH]	Aptamers bound human serum albumin and glycated human serum albumin
WO2015054777	HOSPITAL FOR SICK CHILDREN [CA]	Method of determining disease causality of genome mutations
WO2015051283	RANA THERAPEUTICS INC [US]	Compositions and methods for treating amyotrophic lateral sclerosis
WO2015051188	UNIV WASHINGTON [US]	Heterocyclic molecules for biomedical imaging and therapeutic applications
WO2015051159	UNIV ROCKEFELLER [US]	Amyloid protofibril antibodies and methods of use thereof
WO2015049677	KADIMASTEM LTD [IL]	Directed differentiation of astrocytes from human pluripotent stem cells for use in drug screening and the treatment of amyotrophic lateral sclerosis (als)
WO2015048336	INST SYSTEMS BIOLOGY [US]	Markers for amyotrophic lateral sclerosis (als) and presymptomatic alzheimer's disease (psad)
WO2015048100	KANSAS CITY UNIVERSITY OF MEDICINE AND BIOSCIENCES [US]	Biomarker for early neurodegeneration detection
WO2015041544	HONEYLAB LTD [NZ]	Bee venom compositions and uses

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2015039212	UNIV HEALTH NETWORK UHN TECHNOLOGY DEV AND COMMERCIALIZATION [CA]	Agents directed against a cis rgma/neogenin interaction or lipid rafts and use of the same in methods of treatment
WO2015038963	TEVA PHARMA [IL]; TEVA PHARMA [US] TEL HASHOMER MEDICAL RES INFRA [IL]; HAYARDENY LIAT [IL]; ACHIRON ANAT [IL]; GUREVICH MICHAEL [IL]	Gene expression biomarkers of laquinimod responsiveness
WO2015038958	CALIFORNIA INST OF TECHN [US]	Selective recovery
WO2015038892	MODERNA THERAPEUTICS INC [US]	Polynucleotide compositions containing amino acids
WO2015035063	SANFORD BURNHAM MED RES INST [US]	Modulation of F [gamma] [delta]T cells
WO2015031694	CARIS SCIENCE INC [US]	Oligonucleotide probes and uses thereof
WO2015031084	CAI JIANFENG [US]; CAO CHUANHAI [US]; WU HAIFAN [US]; LI YAQIONG [US]; BAI GE [US]	Methods of synthesizing y- aapeptides, y-aapeptide building blocks, y-aapeptide libraries, and y- aapeptide inhibitors of ab40 aggregates
WO2015063604	IMBERTI LUISA [IT]; SERANA FEDERICO [IT]; CAPRA RUGGERO [IT]	Biomarkers predictive of therapeutic responsiveness to ifn[beta] and uses thereof
WO2015006507	ANNEXON INC [US]; BOSTON CHILDREN S HOSPITAL [US]	Methods of treatment for alzheimer's disease and huntington's disease
WO2015041809	J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE [US]	Small molecule cellular reprogramming to generate neuronal cells
WO2015071857	HOFFMANN LA ROCHE [CH]; PASTEUR INSTITUT [FR]; CENTRE NAT RECH SCIENT [FR]; COMMISSARIAT ENERGIE ATOMIQUE [FR]	Oligopeptide and methods for producing conjugates thereof
WO2015043567	FORSCHUNGSZENTRUM JÜLICH GMBH [DE]	Amyloid-beta-binding peptides and the use thereof for the therapy and diagnosis of alzheimer's dementia
WO2015043566	FORSCHUNGSZENTRUM JÜLICH GMBH [DE]	Cyclic amyloid-beta-binding peptides and the use thereof

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2015060722	UNIQUIRE IP B V [NL]	Aav-5 pseudotyped vector for gene therapy for neurological diseases
WO2015067668	INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE [FR]; UNIV PARIS XI PARIS SUD [FR]; COMMISSARIAT L ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES [FR]; CENTRE NAT RECH SCIENT [FR]; UNIVERSITÉ PARIS DESCARTES [FR]	New alzheimer's disease animal model
WO2015055998	UNIV NOTTINGHAM TRENT [GB]	Transglutaminase inhibitor peptides
WO2015063228	UNIVERSITÄTSKLINIKUM REGENSBURG [DE]	Il-3 blockade in systemic lupus erythematosus and multiple sclerosis
WO2015057939	BIOGEN IDEC INC [US]	Anti-s1p4 antibodies and uses thereof
WO2015059265	CELLECTIS [FR]	Design of rare-cutting endonucleases for efficient and specific targeting dna sequences comprising highly repetitive motives
WO2015044679	UNIV GLASGOW [GB]	Materials and methods for modulating disc1 turnover
WO2015056125	UAB BIOTECHNOLOGINES FARMACIJOS CENTRAS BIOTECHPHARMA [LT]	Fused proteins of interferon alpha 5 with another cytokine and a process for producing thereof
WO2015067432	NORDIC BIOSCIENCE AS [DK]	Biomarkers of alzheimer's disease progression
WO2015062803	KAPURNIOTU APHRODITE [DE]	Modified segments of islet amyloid polypeptide
WO2015040182	ZEALAND PHARMA AS [DK]	Amylin analogues
WO2015032789	COMPREHENSIVE BIOMARKER CT GMBH [DE]; BEIER MARKUS [DE]; SCHEFFLER MATTHIAS [DE]; AKTAS ORHAN [DE]; INGWERSEN JENS [DE]	Mirna based treatment monitoring in autoimmune diseases
WO2015004163	ADX NEUROSCIENCES [BE]; UNIV LEUVEN KATH [BE]	Anti-tau monoclonal antibodies
WO2015047062	UAB PROFARMA [LT]	Fused proteins of granulocyte colony-stimulating factor with other partners of growth factor, preferably with stem cell factor, and method of preparation thereof

Sistema Inmune

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2015070697	SHANGHAI HENGRUI PHARM CO LTD [CN]; JIANGSU HENGRUI MEDICINE CO [CN]	Il-17a conjugate and uses thereof
WO2015069865	JANSSEN BIOTECH INC [US]	Anti-ccl17 antibodies
WO2015065987	IBC PHARMACEUTICALS INC [US]	Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
WO2015061826	UNIV MONASH [AU]; PEPTIDES INTERNATIONAL INC [US]; BAYLOR COLLEGE MEDICINE [US]	Novel scorpion toxin analogue and method for treating autoimmune diseases
WO2015057403	TARIX PHARMACEUTICALS LTD [US]	Compositions and methods for treatment of inflammatory bowel disease
WO2015058173	ABBVIE INC [US]	Stable solid units and methods of making the same
WO2015053803	UNIV MARYLAND [US] ; FRICKE WOLFGANG F [US]; WHITE JAMES R [US]	Methods for distinguishing inflammatory bowel diseases using microbial community signatures
WO2015051451	UNIV MCMASTER [CA]	Diagnosis and monitoring of endometriosis through bdnf and full-length ntrk2 levels
WO2015050957	TREAT S FOR SYSTEMIC LUPUS ERYTHEMATOSUS [US]	Treatments for systemic lupus erythematosus
WO2015051110	OKLAHOMA MED RES FOUND [US]	Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare
WO2015050875	UNIV CALIFORNIA [US]	Endometriosis classifier
WO2015049593	DOSCH HANS-MICHAEL [CA]	Method for reversing recent-onset type 1 diabetes (t1d) by administering substance p (sp)

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2015047941	TRACHTMAN IRA MILTON [US]	Compositions and methods for treatment and prophylaxis of gastrointestinal diseases
WO2015048395	UNIV PITTSBURGH [US]; GIANNOUKAKIS NICK [US]; TRUCCO MASSIMO M [US]	Tolerogenic dendritic cells to treat inflammatory bowel disease
WO2015046407	MEGMILK SNOW BRAND CO LTD [JP]	Prophylactic agent for immunological diseases
WO2015042521	UNIV VIRGINIA PATENT FOUND [US]; SHARMA RAHUL [US]; OKUSA MARK D [US]	Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
WO2015041299	NITTO PHARMACEUTICAL IND LTD [JP]	Exopolysaccharide produced by lactic acid bacterium
WO2015041019	UNIV KYOTO [JP]; ASTELLAS PHARMA INC [JP]	Method for creating endometriotic cells and endometriosis model animal
WO2015040591	UNIV HONG KONG CHINESE [CN]	Sequencing analysis of circulating dna to detect and monitor autoimmune diseases
WO2015039189	UNIV JAMES COOK [AU]	Modified anti-inflammatory proteins and method of use
WO2015039188	UNIV JAMES COOK [AU]	Anti-inflammatory proteins and methods of use
WO2015038960	UNIV CALIFORNIA [US]	Mir-133[alpha] as a marker and therapeutic target for colitis and inflammatory bowel disease
WO2015038075	AGENCY SCIENCE TECH & RES [SG]	Method
WO2015037569	UNIV OKAYAMA NAT UNIV CORP [JP]	Interleukin 10 production stimulating agent
WO2015035063	SANFORD BURNHAM MED RES INST [US]	Modulation of [gamma] [delta]t cells

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2015024450	INST PHARM & TOXICOLOGY AMMS [CN]	Lhrh antagonist derivative and pharmaceutical use thereof
WO2015021924	SHANGHAI 1ST PEOPLES HOSPITAL [CN]	Low molecular polypeptide for preventing and treating inflammation and use thereof
WO2015073580	PFIZER [US]; SQUIBB BRISTOL MYERS CO [US]	Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2015077582	SANOBI BIOTECHNOLOGY [FR]; REGENERON PHARMA [US]	Compositions for the treatment of rheumatoid arthritis and methods of using same
WO2015071837	DRUGGABILITY TECHNOLOGIES HOLDINGS LTD [IE]	Complexes of cyclosporine a and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015071416	BAXTER HEALTHCARE SA [CH]; BAXTER INT [US]	Mif as therapeutic target
WO2015071330	UCB BIOPHARMA SPRL [BE]	Antibodies specific to fcγn
WO2015071229	KEYBIOSCIENCE AG [CH]	Calcitonin mimetics for treating diseases and disorders
WO2015069459	NOVARTIS AG [CH]; EUROSCREEN SA [BE]; BASSILANA FREDERIC [CH]; BAUMGARTEN BIRGIT UTA [CH]; CARTE NATHALIE MARIE-THERESE [CH]; DETHEUX MICHEL [BE]; FALCHETTO ROCCO [CH]; HANNEDOUCHE SÉBASTIEN [BE]; LANNOY VINCENT [BE]; MANSFIELD KEITH [US]; SEUWEN KLAUS PETER [CH]; SUPPLY THOMAS [CH]	Organic compounds
WO2015067763	SIGMOID PHARMA LTD [IE]	Formulations
WO2015067762	SIGMOID PHARMA LTD [IE]	Formulations comprising cyclosporin a
WO2015051379	ABBVIE INC [US]; UNIV MASSACHUSETTS [US]	Dual specific binding proteins directed against immune cell receptors and autoantigens

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2015067636	DELENEX THERAPEUTICS AG [CH]	Binding members to il-1 beta
WO2015052651	HOSPICES CIVILS LYON [FR] ; UNIV CALIFORNIA [US]; UNIV CLAUDE BERNARD LYON [FR]; INST ENSEIGNEMENT SUPERIEUR ET DE RECH EN ALIMENTATION SANTE ANIMALE SCIENCES AGRONOMIQUES ET DE L E [FR]; INST NAT SANTE RECH MED [FR]	Puma protein expression vector and use thereof in gene therapy
WO2015063306	MANCINI ALDO [IT]	Manganese superoxide dismutase variants and uses thereof
WO2015055998	UNIV NOTTINGHAM TRENT [GB]	Transglutaminase inhibitor peptides
WO2015063228	UNIVERSITÄTSKLINIKUM REGENSBURG [DE]	Il-3 blockade in systemic lupus erythematosus and multiple sclerosis
EP2869070	SYSMEX CORP [JP]; INC MEDICAL INSTITUTION OF SHINKO KAI ASS [JP]	Method, system and computer programme product for assisting diagnosis of rheumatoid arthritis
WO2015051234	BIOGEN IDEC INC [US] BIOGEN MA INC [US]	Tweak antagonists for treating lupus nephritis and muscle atrophy
WO2015048083	THE FEINSTEIN INST MEDICAL RES [US]	Peptides inhibiting cold-inducible rna binding protein activity
WO2015056125	UAB BIOTECHNOLOGINES FARMACIJOS CENTRAS BIOTECHPHARMA [LT]	Fused proteins of interferon alpha 5 with another cytokine and a process for producing thereof
WO2015055597	UNIVERSIT DEGLI STUDI DI SIENA [IT]	Anti tnf-alpha compounds and uses thereof
WO2015044332	INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE [FR]; UNIVERSITÉ PARIS DIDEROT PARIS 7 [FR]; UNIVERSITÉ DE VERSAILLES SAINT QUENTIN EN YVELINES [FR]; CENTRE NAT RECH SCIENT [FR]; ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS APHP [FR]	Methods and kits for diagnosing ulcerative colitis in a subject
WO2015038624	IMMUSANT INC [US]	Dosage of a gluten peptide composition

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2015044809	GIELLEPI S P A [IT]	Lactoferrin for the treatment of ibd associated with bacterial invasion
WO2015035162	HARVARD COLLEGE [US]	Cas9 variants and uses thereof
WO2015032620	DSM IP ASSETS BV [NL]	Use of an acidic soft drink to enhance the efficacy of a gluten-digesting enzyme
WO2015067913	DIAGNODUS LTD [GB]	Biomarkers
WO2015069256	GEN HOSPITAL CORP [US]	Eluting matrix and uses thereof
WO2015063616	UTI LIMITED PARTNERSHIP [CA]	Methods and compositions for sustained immunotherapy

Noticias

Publicación de la convocatoria 2015 para la concesión de ayudas del Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia



En el BOE nº 149 de 23 de junio de 2015 se ha publicado la Resolución de 17 de junio de 2015, de la Secretaría de Estado de Investigación, Desarrollo e Innovación, por la que se aprueba la convocatoria para el año 2015 del procedimiento de concesión de ayudas correspondientes al Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia, Subprograma Estatal de Generación de Conocimiento, en el marco del Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016.

[Más información](#)

Publicación en el BOE de la convocatoria 2015 para la concesión de las ayudas al Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad



En el BOE nº 149 del 23 de junio de 2015 ha salido publicada la Resolución de 17 de junio de 2015, de la Secretaría de Estado de Investigación, Desarrollo e Innovación, por la que se aprueba la convocatoria para el año 2015 del procedimiento de concesión de ayudas correspondientes al Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad, en el marco del Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016.

[Más información](#)

La cooperación, elemento clave en la lucha contra las falsificaciones



Como en años anteriores, el Ministerio de Industria, Energía y Turismo, a través de la Oficina Española de Patentes y Marcas (OEPM) y la Asociación Nacional para la Defensa de la Marca (ANDEMA), ha organizado los actos del **Día Mundial Antifalsificación** con la colaboración de la Agencia Estatal de Administración Tributaria (Departamento de Aduanas) y las Fuerzas y Cuerpos de Seguridad del Estado.

Este año, el Día Mundial Antifalsificación –evento que se celebra en 23 países de todo el mundo– se ha celebrado el 2 de junio en la ciudad de Vigo (Pontevedra) como reconocimiento a la importante operación de lucha contra las falsificaciones llevada a cabo en el Mercado de A Pedra. El objetivo del evento, presidido por el Subsecretario de Industria, Energía y Turismo, pasa por concienciar sobre la importancia de la cooperación Público-Privada entre instituciones para erradicar el fenómeno de las falsificaciones. Asimismo, se ha puesto de manifiesto que la responsabilidad del consumidor es clave para la resolución de este problema. En este contexto, también se ha presentado la campaña de sensibilización ‘Ante las falsificaciones, no seas cómplice’.

Más información

